A Phase 3 interventional study of Dapagliflozin 10 mg and Matching Placebo for Dapagliflozin in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 87 sites in 8 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2018-10-31.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.
Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 42nd largest by enrollment, is one of 15 that started in 2015, is one of 47 in phase 3, and was the 57th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, China and 10 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Brazil and 21 more countries
Ages 18+
Junjie Yang · Sites in China
Ages 18–78
Herlev and Gentofte Hospital · Sites in Denmark
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
By country, each count listing its studies:
dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
180 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 53 · Phase 4 77
First in 2005; this study’s year is marked. 15 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 321 is above the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 82 across the 180 interventional studies. Of the 136 that completed or were terminated, 68 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 180 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
345 studies in Diabetes Mellitus, Type 2 by AstraZeneca: 13 open now, 15 under way, 9 of them phase 3. Of 325 finished, 149 (46%) have results posted.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 99th largest by enrollment of the 280 interventional ones that give a count, is one of 15 that started in 2015, is one of 119 in phase 3, and was the 246th registered.
AstraZeneca’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
6 of the studies testing dapagliflozin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07311551Bhavya Bhavya, MDA Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI) | 2026-12 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07614230Junjie YangSGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes | 2027-06-01 |
| NCT07891234Sherihan AboElyazed Mohamed KhalilEffect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance | 2027-10-01 |
| NCT05938712University Health Network, TorontoThe Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients | 2027-10-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Among AstraZeneca’s 345 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes and moderate renal impairment.This study will be conducted at approximately 100 centres from countries across North America and European regions. It is planned to randomize a total of 302 patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Myocardial infarction, Cardiac surgery or revascularization(CABG/PTCA), Unstable angina, Unstable heart failure (HF), HF (NYHA) Class IV, (TIA) or significant cerebrovascular disease, Unstable or previously undiagnosed arrhythmia.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 mg Tablets, Oral, Once daily, 24 weeks
Drug: Dapagliflozin 10 mg
Matching placebo to Dapagliflozin 10 mg tablet. Oral, Once daily, 24 weeks
Drug: Matching Placebo for Dapagliflozin
Tablets administered orally once daily for 24 weeks. Randomization will be stratified by pre-enrolment anti-hyperglycemic therapy
Also known as: Farxiga™
Matching Placebo for Dapagliflozin tablets administered orally once daily for 24 weeks
Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24
To compare the mean change from baseline in HbA1c between dapagliflozin 10 mg and placebo, after 24 weeks of oral administration of double-blind treatment in patients with type 2 diabetes, CKD stage 3A, and moderate renal impairment (CKD 3A; eGFR 45-59 mL/min/1.73m\^2). The "number analyzed" (142 dapaglifozin, 134 placebo) represents the number with change from baseline available at Week 24.
Time frame: Baseline, Week 24
Adjusted Mean Percent Change From Baseline in Total Body Weight at Week 24.
To compare the mean percent change from baseline in total body weight between dapagliflozin 10 mg and placebo, after 24 weeks of oral administration of double-blind treatment in patients with type 2 diabetes, CKD stage 3A, and moderate renal impairment (CKD 3A; eGFR 45-59 mL/min/1.73m\^2). The "number analyzed" represents the number with change from baseline available at Week 24.
Time frame: Baseline, Week 24
Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24.
To compare the mean change from baseline in FPG between dapagliflozin 10 mg and placebo, after 24 weeks of oral administration of double-blind treatment in patients with type 2 diabetes, CKD stage 3A, and moderate renal impairment (CKD 3A; eGFR 45-59 mL/min/1.73m\^2). The "number analyzed" represents the number with change from baseline available at Week 24.
Time frame: Baseline, Week 24
Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (SBP) at Week 24.
To compare the mean change from baseline in seated systolic blood pressure (SBP) between dapagliflozin 10 mg and placebo, after 24 weeks of oral administration of double-blind treatment in patients with type 2 diabetes, CKD stage 3A, and moderate renal impairment (CKD 3A; eGFR 45-59 mL/min/1.73m\^2). The "number analyzed" represents the number with change from baseline available at Week 24.
Time frame: Baseline, Week 24
| Milestone | Dapagliflozin 10mg QD | Placebo QD |
|---|---|---|
| Started | 160 | 161 |
| Completed | 156 | 154 |
| Not completed | 4 | 7 |
| Withdrew: Lost to follow-up | 2 | 4 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Other eligibility criteria | 1 | 2 |
To compare the mean change from baseline in HbA1c between dapagliflozin 10 mg and placebo, after 24 weeks of oral administration of double-blind treatment in patients with type 2 diabetes, CKD stage 3A, and moderate renal impairment (CKD 3A; eGFR 45-59 mL/min/1.73m\^2). The "number analyzed" (142 dapaglifozin, 134 placebo) represents the number with change from baseline available at Week 24.
| percent | Dapagliflozin | Placebo |
|---|---|---|
| Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 | -0.37 ± 0.10 | -0.03 ± 0.10 |
To compare the mean percent change from baseline in total body weight between dapagliflozin 10 mg and placebo, after 24 weeks of oral administration of double-blind treatment in patients with type 2 diabetes, CKD stage 3A, and moderate renal impairment (CKD 3A; eGFR 45-59 mL/min/1.73m\^2). The "number analyzed" represents the number with change from baseline available at Week 24.
| percent change | Dapagliflozin | Placebo |
|---|---|---|
| Adjusted Mean Percent Change From Baseline in Total Body Weight at Week 24. | -3.42 ± 0.32 | -2.02 ± 0.32 |
To compare the mean change from baseline in FPG between dapagliflozin 10 mg and placebo, after 24 weeks of oral administration of double-blind treatment in patients with type 2 diabetes, CKD stage 3A, and moderate renal impairment (CKD 3A; eGFR 45-59 mL/min/1.73m\^2). The "number analyzed" represents the number with change from baseline available at Week 24.
| mg/dL | Dapagliflozin | Placebo |
|---|---|---|
| Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24. | -21.46 ± 5.20 | -4.87 ± 5.13 |
To compare the mean change from baseline in seated systolic blood pressure (SBP) between dapagliflozin 10 mg and placebo, after 24 weeks of oral administration of double-blind treatment in patients with type 2 diabetes, CKD stage 3A, and moderate renal impairment (CKD 3A; eGFR 45-59 mL/min/1.73m\^2). The "number analyzed" represents the number with change from baseline available at Week 24.
| mmHg | Dapagliflozin | Placebo |
|---|---|---|
| Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (SBP) at Week 24. | -4.8 ± 1.5 | -1.7 ± 1.5 |
Collected over Non-serious AEs were included up to the last day of double-blind treatment + 4 days. SAEs were recorded from the time of Informed Consent through included up to the last day of double-blind treatment + 30 days (or to the end of the 3-week follow-up period, whichever came first).. Non-serious events are listed at a 5.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dapagliflozin 10mg QD | 0/160 (0%) | 9/160 (5.6%) | 0/160 (0%) |
| Placebo | 0/161 (0%) | 14/161 (8.7%) | 0/161 (0%) |
| Event | Dapagliflozin 10mg QD | Placebo |
|---|---|---|
| Acute coronary syndromeCardiac disorders | 1/160 | 0/161 |
| Acute myocardial infarctionCardiac disorders | 1/160 | 0/161 |
| Myocardial ischaemiaCardiac disorders | 1/160 | 0/161 |
| Gingival bleedingGastrointestinal disorders | 1/160 | 0/161 |
| Diabetic gangreneInfections and infestations | 1/160 | 0/161 |
| Diabetic metabolic decompensationMetabolism and nutrition disorders | 1/160 | 0/161 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 1/160 | 0/161 |
| Ischaemic strokeNervous system disorders | 1/160 | 1/161 |
| SyncopeNervous system disorders | 1/160 | 0/161 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/160 | 1/161 |
| Age, Continuous(Years) | Dapagliflozin 10mg QD | Placebo | Total |
|---|---|---|---|
| Mean | 65.3 ± 6.22 | 66.2 ± 6.49 | 65.8 ± 6.36 |
| Age, Customized(Participants) | Dapagliflozin 10mg QD | Placebo | Total |
|---|---|---|---|
| < 65 Years | 64 | 46 | 110 |
| >= 65 Years | 96 | 115 | 211 |
| Sex: Female, Male(Participants) | Dapagliflozin 10mg QD | Placebo | Total |
|---|---|---|---|
| Female | 69 | 70 | 139 |
| Male | 91 | 91 | 182 |
| Race/Ethnicity, Customized(Participants) | Dapagliflozin 10mg QD | Placebo | Total |
|---|---|---|---|
| American Indian Or Alaska Native | 2 | 0 | 2 |
| Asian | 5 | 8 | 13 |
| Black Or African American | 11 | 12 | 23 |
| Other | 1 | 1 | 2 |
| White | 141 | 140 | 281 |
| Body Mass Index(kg/m^2) | Dapagliflozin 10mg QD | Placebo | Total |
|---|---|---|---|
| Mean | 32.6 ± 4.7 | 31.6 ± 5.0 | 32.1 ± 4.9 |
| Estimated Glomular Filtration Rate (eGFR)(mL/min/1.73 m^2) | Dapagliflozin 10mg QD | Placebo | Total |
|---|---|---|---|
| Mean | 51.8 ± 4.1 | 51.6 ± 3.8 | 51.7 ± 3.9 |
| Urine Albumin-to-Creatinine Ratio (UACR)(mg/g) | Dapagliflozin 10mg QD | Placebo | Total |
|---|---|---|---|
| Mean | 226.91 ± 566.67 | 246.52 ± 775.49 | 236.78 ± 678.81 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2015 to primary completion in Nov 2017, 28 months.
Results were first posted in Oct 2018, 11 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 28 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapagliflozin